Richard Scott Struthers - Apr 13, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
President & CEO, Director
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Apr 13, 2022
Transactions value $
-$3,719,625
Form type
4
Date filed
4/15/2022, 06:00 PM
Previous filing
Apr 7, 2022
Next filing
Oct 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$627K -24.7K -2.84% $25.42 845K Apr 13, 2022 By Family Trust 1 F1, F2
transaction CRNX Common Stock Sale -$1.19M -44.8K -5.3% $26.52 800K Apr 13, 2022 By Family Trust 1 F1, F3
transaction CRNX Common Stock Sale -$1.9M -69.2K -8.65% $27.53 731K Apr 13, 2022 By Family Trust 1 F1, F4
holding CRNX Common Stock 57.4K Apr 13, 2022 Direct
holding CRNX Common Stock 1K Apr 13, 2022 By Spouse
holding CRNX Common Stock 90K Apr 13, 2022 By Family Trust 2
holding CRNX Common Stock 90K Apr 13, 2022 By Family Trust 3
holding CRNX Common Stock 90K Apr 13, 2022 By Family Trust 4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $25.4247 per share. The range of actual sales prices on the transaction date was $25.00 to $25.98 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.
F3 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $26.5229 per share. The range of actual sales prices on the transaction date was $26.02 to $27.005 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.
F4 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.5277 per share. The range of actual sales prices on the transaction date was $27.02 to $27.845 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.